Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $0.0010 USD
Change Today 0.00 / 0.00%
Volume 0.0
IMMB On Other Exchanges
Symbol
Exchange
OTC US
As of 4:30 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).

immunotech laboratories inc (IMMB) Snapshot

Open
--
Previous Close
$0.0010
Day High
--
Day Low
--
52 Week High
05/5/14 - $0.04
52 Week Low
08/11/14 - $0.0001
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
$36.27
Shares Outstanding
60.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOTECH LABORATORIES INC (IMMB)

Related News

No related news articles were found.

immunotech laboratories inc (IMMB) Related Businessweek News

No Related Businessweek News Found

immunotech laboratories inc (IMMB) Details

Immunotech Laboratories, Inc., a development stage company, engages in the research and development of protein-based therapeutic and diagnostic products with applications in HIV/AIDS. The company holds licensing rights for the irreversible pepsin fraction (IPF) peptide molecule for the treatment and prevention of HIV/AIDS indication. It is developing novel therapeutic molecules for the treatment of HIV/AIDS, as well as for pediatric HIV/AIDS treatment, pre-natal HIV/AIDS treatment, and preventive HIV/AIDS vaccine. The company is based in Glendale, California.

4 Employees
Last Reported Date: 01/5/11

immunotech laboratories inc (IMMB) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

immunotech laboratories inc (IMMB) Key Developments

Immunotech Laboratories, Inc. and Immunotech Laboratories, BG Enter into Agreement with Uldic Investment to Market Potential Ebola Virus Disease Treatment in Africa

Immunotech Laboratories, Inc. and Immunotech Laboratories, BG announced that they have successfully completed negotiations with Uldic Investment Pvt. Ltd., located in Zimbabwe, to pursue the development of market opportunities related to the deadly Ebola virus, and to conduct human clinical trials using the Company's HIV/AIDS and Hepatitis C virus treatment, Immune Therapeutic Vaccine-1 (ITV-1), in Sub-Saharan West Africa. With the establishment of an African operation, Immunotech hopes to fulfill the Company's vision of bringing a therapy based on the patented Inactivated Pepsin Fraction (IPF) protein developed by Immunotech for infectious diseases such as HIV/AIDS, Hepatitis C and a new potential initiative, the Ebola virus. In parts of Africa, approved experimental treatments are permitted, and with the Ebola outbreak, Immunotech expects that it can market its treatment for infectious diseases through the Company's new agreement with Uldic. ITV-1 is a suspension of Inactivated Pepsin Fraction (IPF), which studies have shown is promising in combination with protease inhibitors in the treatment of the HIV/AIDS virus. IPF is a platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects seen in the anti-retrovirals in use. IPF has not shown itself to be subject to viral resistance, and it is cost effective.

Immunotech Laboratories, Inc and Immunotech Laboratories, BG. Announces Successful Completion of Phase I and Phase II Field Trials of HIV/AIDS and Hepatitis C Virus Treatment

Immunotech Laboratories, Inc. and Immunotech Laboratories, BG. recently announced the successful completion of Phase I and Phase II field trials in Bulgaria of the company's HIV/AIDS and Hepatitis C virus treatment and have begun negotiations for sites in Macedonia and Serbia for Phase III testing on human patients. The clinical test are being conducted through Immunotech Laboratories, BG (IMMB-BG) Since 2013 IMMB-BG hired and funded the Clinical Research Organization to conduct all preclinical and monitoring phase III clinical studies. The product for the Bulgarian study was produce under GMP conditions by a US. Contract Manufacturing Facility. The successful completion of Phase III clinical study testing would enable Immunotech Laboratories to move forward using the Phase I, II, & III clinical trial results, for the FDA application pertaining to legal use of the treatment for HIV/AIDS and Hepatitis 'C' patients in the USA.

Immunotech Laboratories, Inc. Announces Completion of Phase I and Phase II Field Trials of Patented Treatment of the HIV/AIDS and Hepatitis C Viruses

Immunotech Laboratories, Inc. announced that the Phase I and Phase II field trials in Bulgaria of the company's HIV/AIDS and Hepatitis C virus treatment ('ITV-1 Treatment') have been completed. The clinical test are being conducted through Immunotech Laboratories, BG. Since 2013, IMMB-BG hired and funded the Clinical Research Organization to conduct all preclinical and monitoring Phase III clinical studies. The product for the Bulgarian study was produced under GMP conditions by a U.S. Contract Manufacturing Facility. The toxicity testing of ITV-1 on animals has also been completed as well as a complete pharmacokinetics (PK) analysis of how the treatment is distributed through the blood system. The company is making its application for the permit to move to Phase III full scale clinical testing on patients. The initial testing will begin upon receipt of the Phase III permit which the Company expects to receive within 60 days of acceptance of the application.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMMB:US $0.00 USD 0.00

IMMB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMMB.
View Industry Companies
 

Industry Analysis

IMMB

Industry Average

Valuation IMMB Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOTECH LABORATORIES INC, please visit www.immunotechlab.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.